Company intelligence / Profile preview
LIfT BioSciences
London, England, United Kingdomliftbiosciences.com ↗
- Ownership
- Private
- Employees
- ~23
- Development stage
- Preclinical
01
Overview
Strong preclinical data show that IMANs can directly kill cancer cells and modulate the tumor microenvironment to recruit additional immune responses. The company has not yet reported human clinical results but plans a Phase I trial to demonstrate safety, tolerability, and immune recruitment.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Allogeneic cell therapy (neutrophil-based)Engineered cell therapy (CAR IMANs)Immunomodulatory Alpha Neutrophils (IMANs)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Gift of Life Biologics – sourcing HSC donors for scalable manufacturingUniversity of Galway – clinical trial collaborationHookeBio – R&D/manufacturing support in Ireland
Beyond the preview
Go deeper on LIfT BioSciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LIfT BioSciences.